These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 8287633)

  • 1. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.
    Chanson P; Timsit J; Harris AG
    Clin Pharmacokinet; 1993 Nov; 25(5):375-91. PubMed ID: 8287633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Octreotide, analog of somatostatin. Pharmacological properties and therapeutic applications in pituitary endocrine tumors].
    Chanson P; Timsit J; Harris AG
    Presse Med; 1993 Dec; 22(40):2009-16. PubMed ID: 7907419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
    Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.
    Harris AG
    Gut; 1994; 35(3 Suppl):S1-4. PubMed ID: 7911441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical use of somatostatin analogues in the treatment of cancer.
    Lamberts SW; Krenning EP; Klijn JG; Reubi JC
    Baillieres Clin Endocrinol Metab; 1990 Mar; 4(1):29-49. PubMed ID: 1975166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide, a new somatostatin analogue.
    Katz MD; Erstad BL
    Clin Pharm; 1989 Apr; 8(4):255-73. PubMed ID: 2653711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
    Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Breeman WA; Lamberts SW
    Endocrinology; 1995 Sep; 136(9):3698-706. PubMed ID: 7649075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide treatment of acromegaly.
    Wass JA
    Horm Res; 1990; 33 Suppl 1():1-5; discussion 6. PubMed ID: 2358294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
    Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
    Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas.
    Bertherat J; Chanson P; Dewailly D; Dupuy M; Jaquet P; Peillon F; Epelbaum J
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1577-83. PubMed ID: 7903312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly.
    Tauber JP; Babin T; Tauber MT; Vigoni F; Bonafe A; Ducasse M; Harris AG; Bayard F
    J Clin Endocrinol Metab; 1989 May; 68(5):917-24. PubMed ID: 2565913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
    Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
    Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.